JP4291417B2 - 放射性同位体によって標識されたペプチドのための放射線保護剤 - Google Patents
放射性同位体によって標識されたペプチドのための放射線保護剤 Download PDFInfo
- Publication number
- JP4291417B2 JP4291417B2 JP50281899A JP50281899A JP4291417B2 JP 4291417 B2 JP4291417 B2 JP 4291417B2 JP 50281899 A JP50281899 A JP 50281899A JP 50281899 A JP50281899 A JP 50281899A JP 4291417 B2 JP4291417 B2 JP 4291417B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- radiolabeled
- povidone
- peptide
- mci
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 101
- 230000003537 radioprotector Effects 0.000 title claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 29
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 142
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 142
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 138
- 229940069328 povidone Drugs 0.000 claims abstract description 134
- 239000000203 mixture Substances 0.000 claims abstract description 125
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 109
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 53
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 53
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 47
- 239000003381 stabilizer Substances 0.000 claims abstract description 35
- 229940124553 radioprotectant Drugs 0.000 claims abstract description 32
- 230000015556 catabolic process Effects 0.000 claims abstract description 13
- 238000006731 degradation reaction Methods 0.000 claims abstract description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 16
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 16
- 239000000718 radiation-protective agent Substances 0.000 claims description 13
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 238000002372 labelling Methods 0.000 claims description 10
- 230000002285 radioactive effect Effects 0.000 claims description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- 239000011630 iodine Substances 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 229960004063 propylene glycol Drugs 0.000 claims description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 6
- 229960005219 gentisic acid Drugs 0.000 claims description 6
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 5
- 229940099500 cystamine Drugs 0.000 claims description 5
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 5
- 229960002086 dextran Drugs 0.000 claims description 5
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 5
- 229960003151 mercaptamine Drugs 0.000 claims description 5
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 5
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000006069 physical mixture Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 32
- 108090000623 proteins and genes Proteins 0.000 abstract description 32
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract description 6
- 230000001950 radioprotection Effects 0.000 abstract description 5
- 239000000047 product Substances 0.000 description 50
- 230000000694 effects Effects 0.000 description 38
- 238000009472 formulation Methods 0.000 description 28
- 238000012360 testing method Methods 0.000 description 28
- 230000005855 radiation Effects 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 230000027455 binding Effects 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 230000004224 protection Effects 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 238000000163 radioactive labelling Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 238000003608 radiolysis reaction Methods 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011814 protection agent Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011363 radioimmunotherapy Methods 0.000 description 3
- 239000012217 radiopharmaceutical Substances 0.000 description 3
- 229940121896 radiopharmaceutical Drugs 0.000 description 3
- 230000002799 radiopharmaceutical effect Effects 0.000 description 3
- 229920003072 Plasdone™ povidone Polymers 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000004223 radioprotective effect Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LLLWMXQKXWIRDZ-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one Chemical compound C=CN1CCCC1=O.C=CN1CCCC1=O LLLWMXQKXWIRDZ-UHFFFAOYSA-N 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011885 in vitro diagnostic (IVD) kits Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4838797P | 1997-06-03 | 1997-06-03 | |
| US60/048,387 | 1997-06-03 | ||
| US08/918,525 US5961955A (en) | 1997-06-03 | 1997-08-21 | Radioprotectant for peptides labeled with radioisotope |
| US08/918,525 | 1997-08-21 | ||
| PCT/US1998/011428 WO1998055154A1 (en) | 1997-06-03 | 1998-06-03 | Radioprotectant for peptides labeled with radioisotope |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002516612A JP2002516612A (ja) | 2002-06-04 |
| JP2002516612A5 JP2002516612A5 (enExample) | 2005-12-22 |
| JP4291417B2 true JP4291417B2 (ja) | 2009-07-08 |
Family
ID=26726075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50281899A Expired - Fee Related JP4291417B2 (ja) | 1997-06-03 | 1998-06-03 | 放射性同位体によって標識されたペプチドのための放射線保護剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US5961955A (enExample) |
| EP (1) | EP1003560B1 (enExample) |
| JP (1) | JP4291417B2 (enExample) |
| AT (1) | ATE249845T1 (enExample) |
| AU (1) | AU743823B2 (enExample) |
| CA (1) | CA2290987A1 (enExample) |
| DE (1) | DE69818272T2 (enExample) |
| DK (1) | DK1003560T3 (enExample) |
| ES (1) | ES2212304T3 (enExample) |
| IL (1) | IL133271A (enExample) |
| NO (1) | NO315693B1 (enExample) |
| NZ (1) | NZ502029A (enExample) |
| PT (1) | PT1003560E (enExample) |
| WO (1) | WO1998055154A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5961955A (en) * | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| JP2002516883A (ja) * | 1998-06-02 | 2002-06-11 | ザ ダウ ケミカル カンパニー | 近接照射療法のための放射性ヨウ素化フェノール |
| US20020102208A1 (en) * | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| KR100330733B1 (ko) * | 1999-11-30 | 2002-04-03 | 노광 | 폴리에틸렌글리콜포스페이트, 그의 합성방법 및 그를방사능보호제로 사용하는 방법 |
| WO2002022000A2 (en) * | 2000-09-15 | 2002-03-21 | Sloan Kettering Institute For Cancer Research | Targeted alpha particle therapy using actinium-225 conjugates |
| HUP0304083A2 (hu) * | 2001-02-26 | 2004-03-29 | Bristol-Myers Squibb Pharma Company | Radiofarmakon kompozíciók, előállításuk és eljárás radiofarmakonok pufferolására |
| US6972324B2 (en) * | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
| US7238338B1 (en) * | 2001-06-22 | 2007-07-03 | Triumf | System and method for the large scale labeling of compounds with radiohalogens |
| US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| WO2003105762A2 (en) * | 2002-06-14 | 2003-12-24 | Actinium Pharmaceuticals Ltd. | Treating disease using radium-225 |
| US7018614B2 (en) * | 2002-11-05 | 2006-03-28 | Eastern Isotopes, Inc. | Stabilization of radiopharmaceuticals labeled with 18-F |
| MXPA05005558A (es) | 2002-11-26 | 2005-07-26 | Protein Design Labs Inc | Anticuerpos quimericos y humanizados para integrina ( 5 ( 1 que modulan la angiogenesis. |
| EP1444990A1 (en) * | 2003-02-07 | 2004-08-11 | Amersham plc | Improved Radiometal Complex Compositions |
| US7485283B2 (en) * | 2004-04-28 | 2009-02-03 | Lantheus Medical Imaging | Contrast agents for myocardial perfusion imaging |
| JP5230865B2 (ja) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ結合性化合物 |
| DK1851200T3 (da) | 2005-02-25 | 2014-04-14 | Tetralogic Pharm Corp | Dimere iap-inhibitorer |
| US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| AU2006279929A1 (en) * | 2005-08-09 | 2007-02-22 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| EP2049563B1 (en) * | 2006-07-24 | 2014-03-12 | Tetralogic Pharmaceuticals Corporation | Dimeric iap antagonists |
| JP5452223B2 (ja) * | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014238A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| US20100113326A1 (en) * | 2006-07-24 | 2010-05-06 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| EP2116241B1 (en) | 2007-01-26 | 2016-04-27 | Pola Pharma Inc. | Pharmaceutical composition |
| EP2136832B1 (en) | 2007-03-26 | 2015-09-02 | General Regeneratives Limited | Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies |
| AU2009220244B2 (en) | 2008-02-29 | 2014-10-09 | Lantheus Medical Imaging, Inc. | Contrast agents for applications including perfusion imaging |
| TW201021831A (en) * | 2008-11-17 | 2010-06-16 | Genentech Inc | Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
| CN102458396B (zh) | 2009-04-15 | 2017-05-10 | 兰休斯医疗成像公司 | 使用抗坏血酸稳定化放射性药物组合物 |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| EP3323810B1 (en) | 2010-02-08 | 2022-01-05 | Lantheus Medical Imaging, Inc. | Automated reaction system, cassette and apparatus for synthesizing imaging agents |
| GB201013808D0 (en) * | 2010-08-18 | 2010-09-29 | Ge Healthcare Ltd | Peptide radiotracer compositions |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| AU2014216515A1 (en) * | 2013-02-15 | 2015-10-08 | Thomas Jefferson University | Kit for tumor imaging |
| GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
| GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
| EP3094391B1 (en) * | 2014-01-17 | 2024-11-20 | Repligen Corporation | Sterilizing chromatography columns |
| IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
| TWI799366B (zh) * | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| WO2017155937A1 (en) * | 2016-03-07 | 2017-09-14 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
| US11339221B2 (en) | 2017-11-01 | 2022-05-24 | Tufts Medical Center, Inc. | Bispecific antibody constructs and methods of use |
| WO2020219550A1 (en) * | 2019-04-23 | 2020-10-29 | Amgen Inc. | The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations |
| US12043671B2 (en) | 2021-06-16 | 2024-07-23 | Gundersen Lutheran Medical Foundation, Inc. | Antibodies targeting an amphiregulin-derived cell surface neo-epitope |
| US20250019350A1 (en) | 2023-06-16 | 2025-01-16 | Progenics Pharmaceuticals, Inc | Synthesis of the prostate specific membrane antigen (psma) radiolabeled inhibitor [18f]dcfpyl |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE933885C (de) * | 1952-06-22 | 1955-10-06 | Helmut Richard Dr Kanitz | Verfahren zur Herstellung kolloidaler Loesungen radioaktiver Metalle wie radioaktiver Goldisotope |
| US4421735A (en) * | 1980-04-17 | 1983-12-20 | The Massachusetts General Hospital | Radiolabeled diagnostic compositions and method for making the same |
| US4427631A (en) * | 1982-05-27 | 1984-01-24 | Euroceltique, S.A. | Povidone irradiation |
| US4411881A (en) * | 1982-07-12 | 1983-10-25 | New England Nuclear Corporation | Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines |
| EP0111414A3 (en) * | 1982-12-08 | 1985-05-02 | Mallinckrodt, Inc. (a Delaware corporation) | Radiographic imaging agents |
| US4676979A (en) * | 1984-12-31 | 1987-06-30 | Eastern Virginia Medical Authority/Med. Ctr. Hosp. | Method of protecting animals against ionizing radiation |
| US5393512A (en) * | 1985-01-14 | 1995-02-28 | Vanderheyden; Jean-Luc | Stable therapeutic radionuclide compositions and methods for preparation thereof |
| US5061641A (en) * | 1988-04-01 | 1991-10-29 | Immunomedics, Inc. | Method for radiolabeling proteins |
| RO103925B1 (ro) * | 1989-02-27 | 1992-04-26 | Institutul De Chimie Macromoleculara "P.Poni" | Derivat de polivinilpirolidona si procedeu de preparare |
| CA2066779A1 (en) * | 1989-09-22 | 1991-03-23 | Jean-Luc Vanderheyden | Stable therapeutic radionuclide compositions and methods for preparation thereof |
| US5011676A (en) * | 1990-03-27 | 1991-04-30 | Thomas Jefferson University | Method to directly radiolabel antibodies for diagnostic imaging and therapy |
| AU2541592A (en) * | 1991-08-01 | 1993-03-02 | Hybritech Incorporated | Improvements in or relating to modified haptens useful as imaging and therapeutic agents |
| AU2462592A (en) * | 1991-08-29 | 1993-04-05 | Mallinckrodt Medical, Inc. | Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins |
| ES2081717T5 (es) * | 1992-04-30 | 2000-02-16 | Amersham Int Plc | Formulaciones de compuestos radiomarcados. |
| WO1994002174A1 (fr) * | 1992-07-28 | 1994-02-03 | Toray Industries, Inc. | Immunocomplexe |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5961955A (en) * | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
-
1997
- 1997-08-21 US US08/918,525 patent/US5961955A/en not_active Expired - Lifetime
-
1998
- 1998-06-03 IL IL13327198A patent/IL133271A/en not_active IP Right Cessation
- 1998-06-03 AT AT98928875T patent/ATE249845T1/de active
- 1998-06-03 NZ NZ502029A patent/NZ502029A/en not_active IP Right Cessation
- 1998-06-03 DE DE69818272T patent/DE69818272T2/de not_active Expired - Lifetime
- 1998-06-03 WO PCT/US1998/011428 patent/WO1998055154A1/en not_active Ceased
- 1998-06-03 JP JP50281899A patent/JP4291417B2/ja not_active Expired - Fee Related
- 1998-06-03 CA CA002290987A patent/CA2290987A1/en not_active Abandoned
- 1998-06-03 ES ES98928875T patent/ES2212304T3/es not_active Expired - Lifetime
- 1998-06-03 AU AU80570/98A patent/AU743823B2/en not_active Ceased
- 1998-06-03 PT PT98928875T patent/PT1003560E/pt unknown
- 1998-06-03 DK DK98928875T patent/DK1003560T3/da active
- 1998-06-03 EP EP98928875A patent/EP1003560B1/en not_active Expired - Lifetime
-
1999
- 1999-12-02 NO NO19995906A patent/NO315693B1/no not_active IP Right Cessation
- 1999-12-02 US US09/453,985 patent/US6338835B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NO995906L (no) | 1999-12-03 |
| JP2002516612A (ja) | 2002-06-04 |
| DE69818272T2 (de) | 2004-07-01 |
| WO1998055154A1 (en) | 1998-12-10 |
| US6338835B1 (en) | 2002-01-15 |
| DE69818272D1 (de) | 2003-10-23 |
| NO315693B1 (no) | 2003-10-13 |
| IL133271A (en) | 2004-06-01 |
| IL133271A0 (en) | 2001-04-30 |
| DK1003560T3 (da) | 2003-12-01 |
| EP1003560A1 (en) | 2000-05-31 |
| ES2212304T3 (es) | 2004-07-16 |
| AU743823B2 (en) | 2002-02-07 |
| WO1998055154A9 (en) | 1999-04-08 |
| CA2290987A1 (en) | 1998-12-10 |
| US5961955A (en) | 1999-10-05 |
| NO995906D0 (no) | 1999-12-02 |
| AU8057098A (en) | 1998-12-21 |
| ATE249845T1 (de) | 2003-10-15 |
| EP1003560B1 (en) | 2003-09-17 |
| PT1003560E (pt) | 2004-02-27 |
| NZ502029A (en) | 2001-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4291417B2 (ja) | 放射性同位体によって標識されたペプチドのための放射線保護剤 | |
| US6024938A (en) | Lyophilized imaging agent formulation comprising a chemotactic peptide | |
| TWI283178B (en) | Method and kit for efficient radiolabeling of proteins with therapeutic radioisotopes | |
| US5605671A (en) | Radiolabeled neutrophil activating peptides for imaging | |
| EP0670736B1 (en) | Labelled interleukin-8 and medical uses thereof | |
| Rennen et al. | Specific and rapid scintigraphic detection of infection with 99mTc-labeled interleukin-8 | |
| CA2279349C (en) | Ascorbate-stabilized radiopharmaceutical method and composition | |
| van der Laken et al. | Imaging of infection in rabbits with radioiodinated interleukin-1 (α and β), its receptor antagonist and a chemotactic peptide: a comparative study | |
| RU2741794C2 (ru) | Радиофармацевтические растворы с предпочтительными свойствами | |
| US20230011134A1 (en) | Compositions and methods for the treatment of prostate cancer | |
| DeNardo et al. | Are radiometal-labeled antibodies better than iodine-131–labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67–, iodine-131–, and yttrium-90–labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma | |
| US20100047167A1 (en) | Combination therapy in the treatment of cancer | |
| Adams et al. | Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice | |
| KR101274867B1 (ko) | 연조직 질환의 방사선 치료에 사용하기 위한 토륨-227 | |
| Signore et al. | Biological imaging for the diagnosis of inflammatory conditions | |
| Macfarlane et al. | Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′ | |
| Meckel et al. | Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium Paraaminohippurate Coadministration in a Rat Model | |
| Signore et al. | [68Ga] Ga-interleukin-2 for imaging activated T-lymphocytes: biochemical characterization and phase I study in normal subjects | |
| Singh et al. | A simplified kit for instant preparation of technerium-99m human immunoglobulin-G for imaging inflammatory foci | |
| Reynolds et al. | Radiohalogenation of monoclonal antibodies: Experiences with radioiodination of monoclonal antibodies for radioimmunotherapy | |
| Ballantyne et al. | Experience with a commercial preparation of 125I-labelled human albumin for study of albumin metabolism | |
| Tsopelas et al. | Evaluation of 99mTc‐immunoglobulins for imaging infection in the rat | |
| Chopra | 99m Tc-Labeled rituximab, a chimeric murine/human anti-CD20 monoclonal antibody [99m Tc] Rituximab |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050527 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050527 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070706 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081125 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090310 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090403 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120410 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130410 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140410 Year of fee payment: 5 |
|
| LAPS | Cancellation because of no payment of annual fees |